Skip to main content

troriluzole

troriluzole: 3 clinical trials tracked.

troriluzole evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about troriluzole, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (3)

A Randomized, Double-Blind, Placebo- Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder

NCT04693351Registry updated 2026-05-22·Phase 3
Completed

Primary endpoint: Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)

InterventionalRandomizedquadruple589 enrolledStarted 2021-01Completion 2025-0450 sites · Canada, United StatesBiohaven Pharmaceuticals, Inc.

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

NCT03970447Registry updated 2026-10-01·Phase 2/Phase 3
Recruiting

Primary endpoint: Overall Survival (OS)

InterventionalRandomizedopen2,250 targetStarted 2019-07Completion 2030-0663 sites · Australia, Canada, France, Germany…Global Coalition for Adaptive Research

A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia.

NCT03701399Registry updated 2026-06-24·Phase 3
Active, not recruiting

Primary endpoint: Randomization Phase: Change From Baseline in the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Total Score at Week 48 in SCA Participants

InterventionalRandomizedquadruple299 targetStarted 2019-03Completion 2026-0823 sites · China, United StatesBiohaven Pharmaceuticals, Inc.